SCHEMBL19159691

SCHEMBL19159691

C=C(OCC)c1nn(Cc2ccc(OC)cc2)cc1C(Nc1cc(Cl)c(=O)n(C)c1)c1ccc(Cl)cc1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPBWR1 P48145 3/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ PDE1B Q01064 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ ABCB1 P08183 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ P2RX3 P56373 3/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ MAT2A P31153 1/20 0.33
▸ GABRA2 P47869 1/20 0.33
▸ GABRB2 P47870 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ THRB P10828 1/20 0.32
▸ BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16244426 0.92 NPBWR1 (0.42) NPBWR1TDP1MAPTPOLBABCB1
SCHEMBL19159167 0.91 TDP1 (0.37) NPBWR1TDP1MAPTPOLBABCB1
SCHEMBL16244484 0.88 TDP1 (0.39) NPBWR1TDP1ABCB1KMT2ACNR2
SCHEMBL16244627 0.85 NPBWR1 (0.42) NPBWR1MAPTPOLBABCB1KMT2A
SCHEMBL16244388 0.83 ABCB1 (0.37) TDP1ABCB1KMT2ACNR2RXFP1
SCHEMBL16244695 0.79 PDE4A (0.40) NPBWR1MAPTPOLBKMT2AP2RX3
SCHEMBL16259906 0.76 KDM4E (0.39) NPBWR1TDP1MAPTP2RX3ALDH1A1
SCHEMBL16244935 0.76 KMT2A (0.41) NPBWR1TDP1KMT2AALDH1A1HPGD
SCHEMBL16244757 0.74 P2RX3 (0.41) NPBWR1MAPTP2RX3L3MBTL1BRD4
SCHEMBL19158727 0.73 BRD4 (0.34) ABCB1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004110-B1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2017-07-26 — — EP disclosed
Send feedback